Abstract
AbstractIt is sometimes necessary to restrain kangaroos (Macropus spp) for veterinary treatment or in the course of scientific research, but the associated stresses may induce capture myopathy in wild kangaroos. Judicious use of injectable sedatives can reduce the risk of capture myopathy. Zoletil®, a proprietary mixture of tiletamine and zolazepam, is reported to have a wide safety margin, a small dose volume, and be quick acting for a range of animals. We investigated the dose-response relationship of Zoletil® in 26 western grey kangaroos (Macropus fuliginosus ocydromus). All kangaroos were recumbent within 5-10 min of intramuscular injection with mean (± SD) Zoletil® of 4.55 (± 0.98) mg kg−1. Mean (± SD) time to recovery varied between individuals, 2.07 (± 0.41) h over all occasions, and was independent of dose rate. For animals that were assessed on multiple occasions, mean (± SEM) time to recover was reduced from 2.25 (± 0.09) h on the first occasion to 2.15 (± 0.10) h on the second occasion and 1.81 (± 0.11) h on the third. Since kangaroos sedated with Zoletil® are vulnerable to predation and injury during recovery, we believe they should be supervised until they are able to fend for themselves.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
